Linagliptin Eg

Linagliptin, the active ingredient in Linagliptin Eg, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral dosage form for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Linagliptin Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control when added to diet and exercise. - Combination therapy with metformin: provides additional HbA1c reduction in patients not achieving targets with metformin alone. - Combination therapy with insulin or sulfonylureas: offers further glucose lowering while maintaining a low risk of hypoglycaemia when used appropriately.

Adverse reactions may occur with Linagliptin use.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate head pain. - Dizziness: occasional light‑headedness, especially on standing. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice.

Before initiating Linagliptin, consider the following safety measures.

- Renal impairment: assess kidney function and adjust therapy if needed. - Hepatic impairment: monitor liver enzymes during treatment. - Risk of hypoglycaemia: heightened when combined with insulin or sulfonylureas; adjust co‑medication accordingly. - Pancreatitis: discontinue if persistent severe abdominal pain occurs. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines; awareness of potential interactions is essential.

Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise Linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce Linagliptin effectiveness. - Diuretics: can affect glucose control, requiring monitoring. - ACE inhibitors: monitor renal function when used together.